Mekinist (trametinib) / Novartis, Japan Tobacco, BeiGene 
Welcome,         Profile    Billing    Logout  

195 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mekinist (trametinib) / Novartis, BeiGene
NCT06195228: A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Recruiting
4
200
RoW
dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibdoy, pralsetinib or selpercatinib with or without anti-PD-1 antibdoy, anlotinib or anlotinib plus anti-PD-1 antibody, lenvatinib plus anti-PD-1 antibody, Other Targets: precise treatment based on the target
Fudan University, Inner Mongolia Cancer Hospital Affiliated To Inner Mongolia Medical University, Shanxi Province Cancer Hospital
Advanced Thyroid Cancer Patients Who Received Target Therapy
04/26
04/27
ChiCTR2100045125: Study on the efficacy of trametinib in the treatment of refractory/recurrent langerhans cell histiocytosis in children

Recruiting
4
50
 
Treatment of trametinib
Beijing Children's Hospital, Capital Medical University; Beijing Children’s Hospital, Capital Medical University, self-funded
Langerhans cell histiocytosis
 
 
NCT03975829 / 2018-004459-19: Pediatric Long-Term Follow-up and Rollover Study

Recruiting
4
250
Europe, Canada, Japan, US, RoW
dabrafenib, DRB436, trametinib, TMT212
Novartis Pharmaceuticals, Novartis Pharma AG
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
05/26
05/26
NCT03340506 / 2017-001987-39: Dabrafenib and/or Trametinib Rollover Study

Recruiting
4
100
Europe, Japan, US, RoW
dabrafenib, trametinib
Novartis Pharmaceuticals
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
12/27
12/27
COMBI-AD, NCT01682083 / 2012-001266-15: Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma ().

Checkmark Data from COMBI-AD trial in combination with Mekinist for melanoma at ASCO 2020
May 2020 - May 2020: Data from COMBI-AD trial in combination with Mekinist for melanoma at ASCO 2020
Checkmark Data from COMBI-AD trial in combination with Tafinlar for melanoma at ASCO 2020
May 2020 - May 2020: Data from COMBI-AD trial in combination with Tafinlar for melanoma at ASCO 2020
Checkmark From COMBI-AD trial in combination with Tafinlar at ASCO 2020
More
Completed
3
870
Europe, Canada, Japan, US, RoW
Dabrafenib, GSK2118436, Trametinib, GSK1120212, Placebos
Novartis Pharmaceuticals
Melanoma
06/17
07/23
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
COMBI-i, NCT02967692 / 2016-002794-35: A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Checkmark From COMBI-i trial in combination with Tafinlar and Mekinist for BRAFV600 metastatic melanoma at ESMO 2020
Sep 2020 - Sep 2020: From COMBI-i trial in combination with Tafinlar and Mekinist for BRAFV600 metastatic melanoma at ESMO 2020
Checkmark From COMBI-i trial in combination with Tafinlar and spartalizumab for BRAFV600 metastatic melanoma
Sep 2020 - Sep 2020: From COMBI-i trial in combination with Tafinlar and spartalizumab for BRAFV600 metastatic melanoma
Checkmark From COMBI-i trial in combination with spartalizumab and Mekinist for BRAFV600 metastatic melanoma
More
Active, not recruiting
3
569
Europe, Canada, Japan, US, RoW
Spartalizumab, PDR001, Placebo, Dabrafenib, Trametinib
Novartis Pharmaceuticals
Melanoma
08/20
08/24
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
NCT04940052: Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer

Calendar Jan 2024 - Dec 2024: Data from trial in combination with Tafinlar for differentiated thyroid cancer
Active, not recruiting
3
153
Canada, US, RoW
Dabrafenib, Trametinib, Trametinib placebo, Dabrafenib placebo
Novartis Pharmaceuticals
Differentiated Thyroid Cancer
05/27
06/27
SEACRAFT-2, NCT06346067: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma

Recruiting
3
470
US
Naporafenib, ERAS-254, LXH254, Dacarbazine, DTIC, Temozolomide, Temodar, TMZ, Trametinib, Mekinist
Erasca, Inc.
Advanced or Metastatic NRAS-mutant Melanoma
04/28
12/28
NCT06475989: Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Not yet recruiting
3
264
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Questionnaire Administration, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Refractory Differentiated Thyroid Gland Carcinoma
09/30
09/30
DREAMseq, NCT02224781: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Active, not recruiting
3
300
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
12/24
12/24
NADINA, NCT04949113 / 2021-001492-16: Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

Active, not recruiting
3
423
Europe, US, RoW
Neoadjuvant ipilimumab + nivolumab, Yervoy + Opdivo, Adjuvant nivolumab, Opdivo
The Netherlands Cancer Institute, Bristol-Myers Squibb
Malignant Melanoma Stage III
01/24
12/28
2013-001627-39: LOGS: A randomized phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer of peritoneal cancer (GOG-0281)

Ongoing
2/3
250
Europe
Trametinib, Letrozole, Tamoxifen, Paclitaxel, Pegylated Liposomal Doxorubicin, Topotecan, GSK1120212, Film-coated tablet, Tablet, Concentrate for solution for injection/infusion, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Trametinib, Femara, tamoxifen, Paclitaxel, Caelyx, Hycamptin
NHS Greater Glasgow and Clyde, University of Glasgow, GlaxoSmithKline,
Recurrent low grade serous ovarian or peritoneal cancer, Ovarian or peritoneal cancer which has came back or started to grow again, Diseases [C] - Cancer [C04]
 
 
NCT02101788: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Checkmark Data from P2/3 trial in patients with recurrent low-grade serous ovarian carcinoma
Feb 2022 - Feb 2022: Data from P2/3 trial in patients with recurrent low-grade serous ovarian carcinoma
Active, not recruiting
2/3
260
Europe, US
Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Apo-Tamox, Clonoxifen, Dignotamoxi, Ebefen, Emblon, Estroxyn, Fentamox, Gen-Tamoxifen, Genox, ICI 46,474, ICI-46474, Jenoxifen, Kessar, Ledertam, Lesporene, Nolgen, Noltam, Nolvadex, Nolvadex-D, Nourytam, Novo-Tamoxifen, Novofen, Noxitem, Oestrifen, Oncotam, PMS-Tamoxifen, Soltamox, TAM, Tamax, Tamaxin, Tamifen, Tamizam, Tamofen, Tamoxasta, Tamoxifeni Citras, Zemide, Topotecan, Hycamptamine, Topotecan Lactone, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI), NRG Oncology
Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
04/19
10/24
2020-005053-25: To test the safety, efficacy and tolerability of a drug called trametinib and determine the duration of treatment in children with histiocytic cell hyperplasia refractory to conventional therapy. Sprawdzenie bezpieczeństwa, skuteczności i tolerancji leku o nazwie trametinib oraz określenie czasu leczenia u dzieci z opornymi na konwencjonalną terapię rozrostami z komórek histiocytarnych.

Not yet recruiting
2
12
Europe
Mekinist, Coated tablet, Mekinist
Institute of Mother and Child, Medical Research Agency
histiocytic cell proliferation rozrost komórek histiocytarnych, Neoplasm derived from histiocyte Nowotwór pochodzacy z histiocytów, Diseases [C] - Cancer [C04]
 
 
2019-003573-26: Evaluating the safety and efficacy of Trametinib in Arterio-Venous Malformations that are refractory to standard care

Not yet recruiting
2
20
Europe
Mekinist, Coated tablet, Mekinist
Cliniques universitaires Saint-Luc, Novartis
Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated, Arteriovenous Malformations, Diseases [C] - Cardiovascular Diseases [C14]
 
 
ACTRN12620001229965: TiNT: Trametinib in Neurofibromatosis type 1 associated tumours

Recruiting
2
120
 
Australian and New Zealand Children's Haematology/Oncology Group, Flicker of Hope Foundation Ltd, National Health and Medical Research Council., Wayne Francis Charitable Trust
Plexiform neurofibromatosis, Optic pathway glioma, Neurofibromatosis type 1
 
 
2013-002616-28: A trial with patients who have a tumor that is too big to resect via operation, to treat them with systemic treatment to downsize the tumor, so that after 8 weeks the tumor can be resected and the patient is cured.

Ongoing
2
25
Europe
dabrafenib, trametinib, GSK2118436, GSK1120212, Capsule, Tablet
NKI-AVL, GlaxoSmithKline
unresectable stage III/IV melanoma, skin cancer that has spread out through the body, Diseases [C] - Cancer [C04]
 
 
2013-004966-33: A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanoma

Ongoing
2
25
Europe
Dabrafenib, Trametinib, GSK1120212, Capsule, Film-coated tablet, Tafinlar
UZ Brussel, UZ Brussel
advanced BRAF V600 mutant melanoma, advanced BRAF V600 mutant melanoma, Diseases [C] - Cancer [C04]
 
 
NCT02281734: Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease and BRAF Mutation

Recruiting
2
18
US
dabrafenib, BRAF inhibitor GSK2118436, GSK-2118436A, GSK2118436, Tafinlar, trametinib, GSK1120212, JTP-74057, Mekinist, laboratory biomarker analysis, quality-of-life assessment, quality of life assessment, questionnaire administration
National Cancer Institute (NCI)
Erdheim-Chester Disease
02/15
 
NCT02402790: A Comparative Study Efficacy of Trametinib (CT) in Comparison With Trametinib (MEKINIST)

Active, not recruiting
2
202
Europe, RoW
Trametinib, Trametinib (CT), Mekinist, GSK1120212
Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation
Cancer
03/15
04/17
NCT01951495: A Study of Trametinib and GSK2141795 Multiple Myeloma

Not yet recruiting
2
74
Canada
Trametinib, GSK1120212, GSK2141795
University Health Network, Toronto, National Cancer Institute (NCI)
Multiple Myeloma, Relapsed, Refractory
10/15
03/16
2013-003452-21: Open-Labeled Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. Estudio abierto de dabrafenib en combinación con trametinib en pacientes con melanoma BRAF positivo y metástasis cerebrales.

Ongoing
2
30
Europe
Tafinlar, Trametinib, GSK1218436, GSK1120212, Tafinlar, Tafinlar
GlaxoSmithKline, S.A., GlaxoSmithKline Research & Development Ltd, GSK USA
Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain Pacientes con melanoma BRAF positivo y metástasis cerebrales.
 
 
2016-002941-49: This is a pilot study (n=35 patients in total in two arms) testing the hypothesis that the inhibition of MEK can restore iodine incorporation in BRAF wild type (n=25 patients) and a combined inhibition of BRAF and MEK can restore iodine incorporation in BRAFV600E mutant (n=10 patients), radioiodine-refractory (RAIR) thyroid cancer.

Not yet recruiting
2
35
Europe
Mekinist®, Tafinlar, EU/1/14/931/06, EU/1/13/865/005, EU/1/14/931/02, EU/1/13/865/002, Film-coated tablet, Capsule, hard, Mekinist ®, Tafinlar®
University Hospital Essen (Anstalt des öffentlichen Rechts)
Radio Iodine Refractory Thyroid Cancer, Thyroid cancer, Diseases [C] - Cancer [C04]
 
 
ACTRN12613000737730: An open label, single centre, phase II pilot study of neoadjuvant dabrafenib + trametinib in patients with resectable AJCC Stage IIIB-C BRAF V600 mutation positive melanoma

Active, not recruiting
2
35
 
Melanoma Institute Australia, GlaxoSmithKline Australia
Melanoma
 
 
Neo Combi, NCT01972347: Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
2
35
RoW
Dabrafenib, GSK2118436, Trametinib, GSK1120212
Melanoma Institute Australia
Melanoma
05/17
05/24
NCT02199730: S1320: Intermittent Versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E/K Mutant Melanoma

Recruiting
2
280
US
Dabrafenib, Dabrafenib Mesylate (GSK2118436, GSK2118436A) (NSC-763760), Tafinlar, Trametinib, Trametinib Dimethyl Sulfoxide (GSK1120212B) (NSC-763093), Mekinist
Southwest Oncology Group, National Cancer Institute (NCI)
Melanoma
10/17
07/21
2016-005228-27: A trial to compare giving chemotherapy intermittently to chemotherapy administered continuously to patients with inoperable or metastatic melanoma.

Not yet recruiting
2
150
Europe
dabrafenib, trametinib, Capsule, hard, Film-coated tablet, dabrafenib, trametinib
Cambridge University Hospitals NHS Foundation Trust, National Institute for Health Research
BRAFV600 mutant stage 3 unresectable or metastatic melanoma, Advanced melanoma (skin cancer) which has an abnormal gene called BRAF., Diseases [C] - Cancer [C04]
 
 
2018-004003-39: A trial to assess efficacy in patients with advanced pretreated BRAFV600 wild-type melanoma

Not yet recruiting
2
58
Europe
Trametinib, Dabrafenib, GSK1120212, L01XE23, Film-coated tablet, Capsule, hard, Mekinist (Trametinib), Tafinlar
UZ Brussel, UZ Brussel
ADVANCED PRETREATED BRAFV600 WILD-TYPE MELANOMA, ADVANCED PRETREATED BRAFV600 WILD-TYPE MELANOMA, Diseases [C] - Cancer [C04]
 
 
NCT04439279: Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Active, not recruiting
2
35
US
Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
03/19
03/25
NCT02642042: Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Active, not recruiting
2
60
US
Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Laboratory Biomarker Analysis, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
05/19
03/25
2019-001317-16: The TRAIN study: TRAmetinib In Neurofibromatosis type 1 related symptomatic plexiform neurofibromas De TRAIN studie: TRAmetinib voor Neurofibromatose type 1 gerelateerde pleximorme neurofibromen

Ongoing
2
30
Europe
Film-coated tablet, Mekinist
ErasmusMC, Stichting NF, Novartis
Adult patients (age >17 years) with (mosaic) NF1 with inoperable symptomatic plexiform neurofibromas, Adult patients (age >17 years) with (mosaic) NF1 with inoperable symptomatic plexiform neurofibromas, Diseases [C] - Nervous System Diseases [C10]
 
 
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig

Not yet recruiting
2
30
Europe
Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo
Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark
Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04]
 
 
NCT04439318: Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Active, not recruiting
2
50
US
Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
06/20
12/25
NCT04439357: Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Active, not recruiting
2
4
US
Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
09/20
12/25
2020-004414-35: Improving public cancer care by implementing precision medicine in Norway

Not yet recruiting
2
2000
Europe
Alpelisib, Fulvestrant, imatinib, Hydroxyurea, bortezomib, capmatinib, Dactinomycin, tepotinib, dostarlimab, Capsule, hard, Injection, Infusion, Tablet, Capsule, Solution for injection, Powder and solvent for suspension for injection, Powder for solution for injection, Concentrate for solution for infusion, Alecensa, Erivedge, Phesgo, Rozlytrek, Tecentriq, Avastin, Zelboraf, Cotellic, Mekinist, Tafinlar, Alkeran, Piqray, Lynparza, Pemazyre, Tabrecta, Retsevmo, Tepmetko, Gavreto, Zejula
Oslo University Hospital, Oslo University Hospital
Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible., Patients with a biomarker indicating response to the study drug can be included in the trial. Patients with disease characteristics covered in present indications for the study drug are not eligible., Diseases [C] - Cancer [C04]
 
 
NCT06482086: Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting
2
75
RoW
Anlotinib, Lenvatinib, Sorafenib, Donafenib, Everolimus, Apatinib, Dabrafenib + Trametinib, Cabozantinib, Vandetanib, Entrectinib, Pralsetinib, Larotrectinib
West China Hospital
Locally Advanced Thyroid Gland Carcinoma
12/24
12/25
2021-000087-30: Treatment with the drugs dabrafenib and trametinib before or afteroperation for the tumour papillary craniopharyngioma Behandling med medicinerna dabrafenib och trametinib före eller efteroperation av tumören papillärt kraniopfaryngeom

Not yet recruiting
2
25
Europe
Capsule, hard, Film-coated tablet, Tafinlar, Mekinist
Skane University Hospital, Dept of Endocrinology, Region Skåne, Skane University Hospital
Papillary craniopharyngioma Papillärt kraniofaryngeom, Craniopharyngeoma, benign tumour near the pituitary and hypothalamus Kraniofaryngeom, en godartad tumör belägen vid hypofysen och hypothalamus, Diseases [C] - Cancer [C04]
 
 
2021-001375-16: Study of the effectiveness of drugs selected depending on the molecular profile of diffuse intrinsic pontine glioma (DIPG) Badanie skuteczności leków dobranych w zależności od profilu molekularnego rozlanego glejaka pnia mózgu (diffuse intrinsic pontine glioma, DIPG)

Not yet recruiting
2
100
Europe
Film-coated tablet, Coated tablet, , Mekinist 0,5 mg film-coated tablets, Rapamune 1 mg coated tablets, Rapamune 1mg/ml oral solution
The Children's Memorial Health Institute, Medical Research Agency
diffuse intrinsic pontine glioma rozlany naciekający glejak mostu, brain stem tumor guz pnia mózgu, Diseases [C] - Cancer [C04]
 
 
CDRB436G2201, NCT02684058 / 2015-004015-20: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Checkmark From trial in combination with Tafinlar in BRAF V600mutant glioma
Jun 2022 - Jun 2022: From trial in combination with Tafinlar in BRAF V600mutant glioma
Completed
2
151
Europe, Canada, Japan, US, RoW
Dabrafenib, DRB436, trametinib, TMT212, Carboplatin, Vincristine
Novartis Pharmaceuticals
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma
08/21
04/23
NCT02152995: Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Active, not recruiting
2
34
US
Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Iodine I 124, I-124, Iodine 124, Iodine I-124, Iodine I-131, 131-Iodine, Bound Iodide I-131, I 131, I-131, Iodide I-131, Iodide, I-131, Iodine 131, Iodine-131, Iodotope, Iodotrope, Laboratory Biomarker Analysis, Pharmacodynamic Study, PHARMACODYNAMIC, Pharmacodynamic (PD) study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
08/21
01/25
2021-000689-14: Finnish national phase 2 study to evaluate targeted drug treatment in advanced cancer. Yksilöllistä syövänhoitoa selvittävä kansallinen vaiheen 2 lääketutkimus edenneessä syövässä.

Not yet recruiting
2
250
Europe
abemaciclib, pralsetinib, Tablet, Capsule, hard, Injection, Infusion, Capsule, Stivarga, Alecensa, Cotellic, Erivedge, Phesgo, Rozlytrek, Tecentriq, Zelboraf, Verzenios, Retsevmo, Erleada, Tafinlar, Mekinist, Gavreto, Lynparza
Helsinki University Hospital, Helsinki University Hospital
Patients with an advanced solid tumor for which standard treatment options no longer exist and with acceptable performance status and organ function with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test., Patients with advanced cancer where standard treatment options no longer exist. Potilaat, jotka sairastava edennyttä syöpää, johon tavanomaiset hoitolinjat eivät enää tehoa., Diseases [C] - Cancer [C04]
 
 
2020-005786-14: A randomized and controlled phase II national protocol in non NF1 pediatric and AYA (Adolescent and Young Adults) patients bearing a wild type BRAF gene newly diagnosed comparing a daily oral MEK inhibitor (Trametinib) versus weekly vinblastine during 18 monthsPLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy) Protocole national de phase II des patients pédiatriques et AJA (Adolescents et Jeunes Adultes) non NF1 ayant un gliome de bas grade BRAF non muté en première ligne comparant un traitement par MEK inhibiteur (Trametinib) en prise orale quotidienne versus vinblastine IV hebdomadaire pendant 18 mois

Not yet recruiting
2
134
Europe
MEKINIST, Trametinib 5mg poudre pour solution buvable, Tablet, Powder for solution for injection, Powder for oral solution, MEKINIST, VELBE
Hôpitaux Universitaires de Strasbourg B.1.2, Hôpitaux universitaires de Strasbourg
Histologically proven grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocytoma (PXA) confirmed Gliome de grade 1 / tumeurs glio-neuronales mixtes ou xanthoastrocytome pléomorphe (PXA) histologiquement prouvé et confirmé, Pediatric Low Grade Glioma Gliome de bas grade pédiatrique, Diseases [C] - Cancer [C04]
 
 
MERAIODE, NCT03244956 / 2017-000742-21: Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Active, not recruiting
2
40
Europe
Trametinib, Dabrafenib, 131I, rhTSH
Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
11/21
12/22
COMBI-R2, NCT03754179: Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma

Recruiting
2
63
Europe
Dabrafenib, Tafinlar, DAB, Trametinib, Mekinist, TRA, Hydroxychloroquine, Plaquenil, HCQ
Universitair Ziekenhuis Brussel, University Hospital, Ghent
Melanoma
12/21
07/22
NCT04554680: Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

Recruiting
2
5
RoW
dabrafenib and trametinib
National University Hospital, Singapore, Singapore General Hospital
Thyroid Cancer
12/21
04/22
NCT03149029: Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

Active, not recruiting
2
16
US
Pembrolizumab, Keytruda, Dabrafenib, Tafinlar, Trametinib, Mekinist
Massachusetts General Hospital, Merck Sharp & Dohme LLC
Metastatic Melanoma
12/21
12/24
NeoTrio, NCT02858921: Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Active, not recruiting
2
60
RoW
Dabrafenib, Tafinlar, Trametinib, Mekinist, Pembrolizumab, Keytruda
Melanoma Institute Australia, Merck Sharp & Dohme LLC, Novartis
Melanoma
01/22
11/24
2021-006276-16: A phase 2 clinical research study to examine if trametinib and hydroxychloroquine will improve outcomes for patients with advanced pancreatic cancer.

Not yet recruiting
2
22
Europe
Trametinib, Hydroxychloroquine sulfate, Film-coated tablet, Mekinist®, Hydroxychloroquine sulfate
Cancer Trials Ireland, Cancer Trials Ireland
Metastatic refractory pancreatic cancer., Advanced pancreatic cancer., Diseases [C] - Cancer [C04]
 
 
NCT01723202: Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer

Active, not recruiting
2
53
US
dabrafenib, BRAF inhibitor GSK2118436, GSK2118436, trametinib, GSK1120212, MEKi, Correlative Studies, Pharmacological studies, Tumor pharmacodynamics, PD, PK, PGx
Bhavana Konda, National Comprehensive Cancer Network
Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer
04/22
12/22
NCT04566133: Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Terminated
2
2
US
Trametinib, Mekinist, Hydroxychloroquine, Plaquenil
National Cancer Institute (NCI)
Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
05/22
12/22
Nov IIT- Pyrex, NCT04652258: Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated With Dabrafenib/ Trametinib +/- Immunotherapy

Recruiting
2
20
Europe
Actemra
University of Zurich
Pyrexia
06/22
10/22
NCT03668431: Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Recruiting
2
25
US
Dabrafenib, Tafinlar®, Trametinib, Mekinist®, PDR001
Massachusetts General Hospital, Novartis, Stand Up To Cancer
Metastatic Colorectal Cancer
09/22
12/22
2022-001908-17: Neo- and adjuvant targeted therapy in anaplastic cancer of the thyroid (NEO-ATACT study) Neo-adjuvante en adjuvante behandeling voor anaplastisch carcinoom van de schildklier (NEO-ATACT studie)

Ongoing
2
20
Europe
Capsule, hard, Tablet, Tafinlar, Mekinist
Leiden University Medical Center, Norvartis
BRAF-mutated anaplastic thyroid cancer, Anaplastic thyroid cancer with BRAF mutation, Diseases [C] - Cancer [C04]
 
 
INDIGO, NCT04644432: Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

Recruiting
2
30
Europe
Medication (A specification is listed under each arm), Patient reported outcomes measurement, PRO
Herlev and Gentofte Hospital
Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms, Urogenital Neoplasms
09/22
09/22
NCT04487106: Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Completed
2
21
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
02/23
02/23
NCT05299580 / 2019-004760-21: "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Withdrawn
2
35
Europe
dabrafenib, Trametinib
Fondazione Melanoma Onlus, Novartis Farma S.p.A.
Melanoma
03/23
03/23
ADVL1521, NCT03190915: Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Active, not recruiting
2
10
US
Bone Marrow Aspiration and Biopsy, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI), Children's Oncology Group
Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
03/23
09/24
CAcTUS, NCT03808441: - Circulating Tumour DNA Guided Switch

Active, not recruiting
2
21
Europe
ctDNA analysis
The Christie NHS Foundation Trust, Bristol-Myers Squibb, University of Manchester, Manchester Academic Health Science Centre
Melanoma
04/23
05/24
SARC033, NCT03148275: Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

Completed
2
44
US
Questionnaire Administration, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma, Unresectable Epithelioid Hemangioendothelioma
06/23
06/23
TraMel-WT, NCT04059224: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma

Completed
2
45
Europe
Trametinib, TRA, Mekinist, Dabrafenib, DAB, Tafinlar
Universitair Ziekenhuis Brussel
Stage IV Melanoma, Stage III Melanoma
06/23
06/23
plexifpc, NCT03741101 / 2018-001846-32: Treatment of NF1-related Plexiform Neurofibroma With Trametinib

Active, not recruiting
2
15
Europe
Trametinib, mekinist
Region Skane, Novartis
Neurofibromatosis 1, Child, Neurofibroma, Plexiform
07/24
12/24
NCI-2020-03273, NCT04439292: Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Active, not recruiting
2
35
US
Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
04/25
04/25
ALTER-PATH NeoDT, NCT04310397: Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Completed
2
4
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Spartalizumab, PDR-001, PDR001, Therapeutic Conventional Surgery, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
10/23
10/23
NCT02196181: Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Active, not recruiting
2
280
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
12/24
12/24
ANAPLAST-NEO, NCT04739566: Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer

Withdrawn
2
18
RoW
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
Saint Petersburg State University, Russia
Thyroid Gland Anaplastic Carcinoma
12/23
12/23
NCT03087071: Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

Active, not recruiting
2
59
US
Laboratory Biomarker Analysis, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, MoAb ABX-EGF, Monoclonal Antibody ABX-EGF, Vectibix, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
01/25
01/25
NCT02881242: Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Active, not recruiting
2
14
US
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
Jonsson Comprehensive Cancer Center, Stand Up To Cancer, Novartis, Prostate Cancer Foundation
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
01/24
01/25
NCT06362694: Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

Recruiting
2
10
RoW
Dabrafenib + Trametinib
Saint Petersburg State University, Russia
Anaplastic Thyroid Cancer
03/26
06/26
Combi-Neo, NCT02231775: Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Active, not recruiting
2
58
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
04/25
04/25
NCT04417621 / 2020-000873-26: Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Active, not recruiting
2
134
Europe, US, RoW
LXH254, LTT462, Trametinib, Ribociclib
Novartis Pharmaceuticals
Melanoma
08/24
09/24
MEMBRAINS, NCT03563729 / 2018-000875-34: Melanoma Metastasized to the Brain and Steroids

Recruiting
2
80
Europe
Pembrolizumab Injection [Keytruda], Ipilimumab Injection [Yervoy], Nivolumab Injection [Opdivo], Encorafenib, Binimetinib, Dabrafenib, Trametinib
Inge Marie Svane
Malignant Melanoma
06/24
06/28
NCT04238624: Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Recruiting
2
15
US
Dabrafenib, Trametinib
Memorial Sloan Kettering Cancer Center
Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related Tumors
06/24
06/24
NCT04675710: Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Recruiting
2
30
US
Conventional Surgery, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center
Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma
06/24
06/24
PaTcH, NCT05518110: Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

Recruiting
2
22
Europe
Trametinib, Hydroxychloroquine
Cancer Trials Ireland, Novartis
Pancreatic Cancer
07/24
04/25
NCT01990196: Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Active, not recruiting
2
45
US
degarelix, Firmagon, FE200486, enzalutamide, Xtandi, MDV3100, trametinib, Mekinist, dasatinib, Sprycel, BMS-354825
Jonsson Comprehensive Cancer Center, Medivation, Inc., GlaxoSmithKline, Prostate Cancer Foundation, Astellas Pharma Inc, Novartis
Prostate Cancer
09/24
09/25
NCT04452877: A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Active, not recruiting
2
40
RoW
Dabrafenib, DRB436, Trametinib, TMT212
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
11/24
11/24
RegoMel, NCT05370807: A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma

Recruiting
2
48
Europe
Regorafenib 40 MG Oral Tablet, Triplet therapy
Universitair Ziekenhuis Brussel
Melanoma Stage III, Melanoma Stage IV
12/24
03/25
TRIDeNT, NCT02910700: Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Active, not recruiting
2
52
US
Binimetinib, Dabrafenib, Encorafenib, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study, Trametinib
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
12/24
12/24
I-FIRST, NCT05182931: A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer ( Study)

Recruiting
2
80
RoW
Dabrafenib 75 MG, Tafinlar, Trametinib 2 MG, Mekinist
Olivia Newton-John Cancer Research Institute, Royal North Shore Hospital, Austin Health, Sir Charles Gairdner Hospital, Monash Health, Peter MacCallum Cancer Centre, Australia, Royal Brisbane and Women's Hospital, Eastern Health, The Alfred, Royal Adelaide Hospital
Thyroid Cancer
12/24
12/25
ERRITI, NCT04619316: Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

Recruiting
2
70
Europe
Trametinib 2 MG [Mekinist], Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]
University Hospital, Essen
Metastatic Thyroid Cancer
12/24
12/24
NCT04258046: Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

Recruiting
2
30
US
Trametinib tablet
Stanford University, Boston Children's Hospital
Venous Malformation, Arterial Disease
12/24
12/24
NCT04803318: Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Recruiting
2
100
RoW
Combination of three inhibitors Trametinib, Everolimus and Lenvatinib, Combination of 3 signaling pathway inhibitors specific to MEK, mTOR, and angiogenesis.
Second Affiliated Hospital of Guangzhou Medical University
Solid Tumor, Adult, Hepatocellular Carcinoma
01/29
01/37
NCT06054191: Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

Not yet recruiting
2
40
RoW
Dabrafenib + Trametinib, Capmatinib
Sun Yat-sen University
NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation
03/25
03/27
CA209-8TT, NCT03899155 / 2018-004362-34: Pan Tumor Rollover Study

Recruiting
2
1500
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558-01, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, BMS-986016-01, Nivolumab + Relatlimab, BMS-986213, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
Bristol-Myers Squibb, Exelixis, Novartis, Clovis Oncology, Inc., Janssen Pharmaceuticals
Cancer
08/29
08/29
NCT04544111: PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Active, not recruiting
2
19
US
Trametinib, Dabrafenib, PDR001
Memorial Sloan Kettering Cancer Center
Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Hurthle Cell Thyroid Neoplasia
09/25
09/25
OZUHN-017, NCT06098872: Pilot Study on Trametinib for Surgical Unruptured AVMs

Recruiting
2
10
Canada
Trametinib tablet
University Health Network, Toronto
Arteriovenous Malformations
11/25
11/25
NCT04527549: Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Active, not recruiting
2
84
US
Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Hydroxychloroquine Sulfate, Plaquenil, Placebo Administration, Trametinib Dimethyl Sulfoxide
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
11/25
11/25
NCI-MATCH, NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Checkmark Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
Nov 2019 - Nov 2019: Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
Active, not recruiting
2
6452
US, RoW
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Afatinib, BIBW 2992, BIBW-2992, BIBW2992, Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif, Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capivasertib, AZD5363, Truqap, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Defactinib, PF-04554878, VS-6063, Defactinib Hydrochloride, Echocardiography, EC, Erdafitinib, Balversa, JNJ-42756493, Fexagratinib, ABSK-091, ABSK091, AZD4547, FGFR Inhibitor AZD4547, KB-74810, Ipatasertib, GDC-0068, RG-7440, Laboratory Biomarker Analysis, Larotrectinib, ARRY 470, LOXO 101, LOXO-101, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Osimertinib, AZD-9291, AZD9291, Mereletinib, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, PI3K-beta Inhibitor GSK2636771, GSK-2636771, GSK2636771, Radiologic Examination, Radiologic Evaluation, Radiologic Exam, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Sunitinib Malate, SU011248, SU11248, sunitinib, Sutent, Taselisib, GDC-0032, RO5537381, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herzuma, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Ulixertinib, BVD-523, VRT752271, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Recurrent Uterine Corpus Cancer, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma, Uterine Corpus Cancer
12/25
12/25
MegaMOST, NCT04116541: A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Recruiting
2
455
Europe
HDM201, Closed cohort, Ribociclib, Cabozantinib, Open cohort, Alectinib, Regorafenib, Trametinib, Dabrafenib, Avapritinib
Centre Leon Berard
Malignant Solid Tumor
02/26
11/26
NCT05876806: Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Recruiting
2
30
RoW
Dabrafenib, Trametinib
Se Jun Park
Cancer
03/26
03/26
TRAM, NCT04943224: Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

Recruiting
2
12
Europe
Trametinib, Mekinist
Anna Raciborska, Maria Sklodowska-Curie National Research Institute of Oncology, Łukasiewicz Research Network, Wrocław University of Environmental and Life Sciences
Histiocytosis
03/26
06/26
NCT05988697: Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting
2
36
NA
Combind asprin with Trametinib and Dabrafenib
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NSCLC, BRAF V600E Mutation, Advanced Cancer, Stage IIIB NSCLC, Stage IV NSCLC
09/26
04/27
FINPROVE, NCT05159245: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Recruiting
2
250
Europe
Alectinib, Alecensa, Cobimetinib, Cotellic, Vismodegib, Erivedge, Trastuzumab+Pertuzumab, Phesgo, Entrectinib, Rozlytrek, Atezolizumab, Tecentriq, Vemurafenib, Zelboraf, Regorafenib, Stivarga, Apalutamide, Erleada, Abemaciclib, Verzenio, Selpercatinib, Retevmo, Dabrafenib, Tafinlar, Trametinib, Mekinist, Dabrafenib+Trametinib, Tafinlanr+Mekinist, Pralsetinib, Gavreto
Helsinki University Central Hospital
Advanced Cancer, Solid Tumor, Haematological Malignancy
11/26
11/26
NEO-ATACT, NCT06079333: NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid ( Study)

Recruiting
2
20
Europe
dabrafenib/trametinib
Leiden University Medical Center, Novartis
Anaplastic Thyroid Cancer
01/27
01/28
TRAM-01, NCT03363217: Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Active, not recruiting
2
114
Canada
Trametinib, Mekinist
St. Justine's Hospital, Montreal Children's Hospital of the MUHC, CHU de Quebec-Universite Laval
Low-grade Glioma, Plexiform Neurofibroma, Central Nervous System Glioma
03/27
03/27
MatchMel, NCT02645149: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

Recruiting
2
1000
RoW
Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study
Melanoma Institute Australia, Novartis
Melanoma
07/27
12/28
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Swecranio, NCT05525273: Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma

Recruiting
2
25
Europe
Oral dabrafenib and trametinib
Eva Marie Erfurth, MD, PhD, Novartis
Craniopharyngioma
09/27
04/28
 

Download Options